TABLE 1.
Demographic characteristics of 2357 Parkinson's disease patients and 1182 controls stratified by cohort
| Site | Cohort | n | Age (y), mean (SD) | Female % | DURILL (y), mean (SD) | ||||
|---|---|---|---|---|---|---|---|---|---|
| HC | PD | HC | PD | HC | PD | HC | PD | ||
| Amsterdam | Amsterdam I | 44 | 138 | 56.5 (9.48) | 63.1 (10.81) | 39 | 38 | NA | 2.1 (3.39) |
| Amsterdam II | 0 | 61 | NA | 62.5 (7.08) | NA | 39 | NA | 5.3 (3.54) | |
| Bern | BE I | 23 | 52 | 54.1 (9.78) | 62.9 (10.38) | 30 | 52 | NA | 12.4 (4.29) |
| BE II | 30 | 3 | 68.2 (4.59) | 59.7 (6.66) | 70 | 67 | NA | 11.3 (7.57) | |
| Campinas | UNICAMP | 138 | 110 | 58.9 (7.91) | 59.9 (10.2) | 63 | 34 | NA | 7.3 (6.41) |
| Chang Gung | CGU | 223 | 327 | 61 (7.28) | 60.1 (9.63) | 54 | 43 | NA | 8.7 (6.33) |
| Charlottesville | UVA I | 0 | 116 | NA | 63.7 (8.52) | NA | 28 | NA | 9.7 (5.09) |
| UVA II | 0 | 37 | NA | 62.4 (9.59) | NA | 14 | NA | 8.7 (3.64) | |
| UVA III | 0 | 24 | NA | 70.8 (6.77) | NA | 29 | NA | 7.7 (3.23) | |
| Christchurch | PDNZ | 39 | 209 | 67.5 (8.52) | 69.4 (7.77) | 33 | 26 | NA | 5.7 (5.57) |
| Donders | Donders | 23 | 59 | 62.7 (10.29) | 60.8 (10.07) | 48 | 44 | NA | 4.4 (3.79) |
| Graz | PROMOVE/ASPS I | 124 | 100 | 63.4 (10.07) | 63.2 (10.15) | 27 | 29 | NA | 4.7 (4.77) |
| PROMOVE/ASPS II | 0 | 23 | NA | 64 (9.9) | NA | 22 | NA | 4 (5.69) | |
| Liege | Liege I | 33 | 30 | 65.8 (4.29) | 65.9 (6.61) | 45 | 37 | NA | 7.2 (5.32) |
| Liege II | 43 | 45 | 64.8 (8.33) | 66.9 (8.24) | 49 | 44 | NA | 6 (3.93) | |
| Milan | Milan | 10 | 44 | 53.3 (10.53) | 57.8 (7.71) | 70 | 32 | NA | 11.4 (3.38) |
| NEUROCON | NEUROCON | 15 | 27 | 66.7 (11.74) | 68.7 (10.55) | 80 | 37 | NA | NA |
| NW‐England | NW‐England I | 22 | 32 | 70 (7.27) | 69.9 (8.58) | 45 | 19 | NA | 6.8 (4.42) |
| NW‐England II | 13 | 14 | 64.6 (4.13) | 65 (5.67) | 38 | 29 | NA | 9.2 (6.02) | |
| ON Japan | ON Japan | 15 | 30 | 63.3 (5.25) | 67.6 (6.81) | 53 | 57 | NA | NA |
| Oxford | Oxford DISCOVERY | 57 | 115 | 65.6 (8.2) | 63.9 (10.05) | 39 | 36 | NA | 2.3 (1.58) |
| Pennsylvania | UDALL/U19 | 11 | 112 | 70.1 (5.86) | 66.4 (7.87) | 55 | 32 | NA | 7.3 (5.48) |
| PPMI | PPMI 1‐21 | 163 | 347 | 63.6 (16.73) | 62.9 (8.19) | 36 | 35 | NA | 0.6 (0.52) |
| Rome SLF | Rome SLF | 125 | 239 | 36.6 (10.63) | 62.7 (10.19) | 41 | 37 | NA | 4.9 (4.17) |
| Stanford | Stanford | 11 | 44 | 65.6 (6.47) | 68.6 (8.49) | 82 | 50 | NA | 5.6 (3.44) |
| Tao Wu | Tao Wu | 20 | 19 | 64.8 (5.58) | 65 (4.45) | 40 | 47 | NA | 5.3 (4) |
| Total | 1182 | 2357 | 59.4 (12.31) | 63.4 (9.77) | 46 | 36 | NA | 5.5 (5.47) | |
NA, not available; n, sample size; HC, healthy control; PD, Parkinson's disease; PPMI, Parkinson's Progression Markers Initiative; SD, standard deviation; DURILL, duration of illness; MoCA, Montreal Cognitive Assessment.